Improving tumor detection and treatment using a special fluorescent probe
Official title: Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment
Funded at Saint Joseph's University · NIH-10818914 · Data updated 2026-11-12
This study is looking at ways to make tumors easier to see during surgery by using a special substance called aminolevulinic acid, which helps doctors remove cancer more effectively, so patients can have better outcomes.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Joseph's University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 1, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $118,970 |
| NIH project number | 3R15CA268200-03S1 |
| Project ID | NIH-10818914 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing surgery for malignant tumors who could benefit from enhanced imaging techniques.
✕Less likely to help
Patients with non-malignant tumors or those not requiring surgical intervention may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of aminolevulinic acid (ALA) and its metabolite protoporphyrin IX (PpIX) for better imaging and treatment of tumors during surgery. By investigating the factors that limit the fluorescence of PpIX in tumors, the research aims to improve the visibility of tumors, allowing for more precise removal and treatment. The study will explore the use of existing medications to increase the fluorescence of PpIX, potentially leading to better outcomes for patients undergoing tumor resection. Patients may benefit from improved surgical techniques that allow for more complete removal of cancerous tissues.
Why it matters
Potential benefit: If successful, this research could lead to more effective tumor surgeries and improved cancer treatment outcomes.
How similar studies have gone: Previous research has shown promise in using fluorescence-guided techniques for tumor resection, indicating potential for success in this approach.
Where this research is happening
-
Saint Joseph's University
Philadelphia, United States Active
Researchers
- Principal investigator: Chen, Bin — Saint Joseph's University
- Study coordinator: Chen, Bin
Related research
Other NIH-funded projects on the same topics.
-
How GABA-A receptors may drive triple-negative breast cancer
This project looks into whether GABA-A receptor signals on tumor cells help triple-negative breast cancer grow, move, and resist treatment.
-
How non-centrosomal microtubules control cell movement and shape
This study is looking at how certain tiny structures in our cells help them move and stay organized, which is important for understanding diseases like heart disease and cancer, and it’s for anyone interested in how our cells work and respond to health challenges.
-
Improving tumor removal using a special fluorescent probe
This study is looking at a special tool that helps surgeons see tumors better during surgery, using a fluorescent substance that makes the tumors glow, so they can remove them more completely and improve recovery for patients with solid tumors.
-
Investigating a new protein that regulates DNA damage and repair in triple negative breast cancer
This study is looking at a protein called CAPER to see how it affects the way triple negative breast cancer cells handle DNA damage, with the hope of finding better treatments that can either kill these cancer cells or help them respond better to chemotherapy and radiation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.